Current Heart Failure Reports

, Volume 6, Issue 4, pp 257–264 | Cite as

Tachycardia-mediated cardiomyopathy: Recognition and management

  • Rakesh Gopinathannair
  • Renee M. Sullivan
  • Brian OlshanskyEmail author


Tachycardia-mediated cardiomyopathy is a cause of ventricular dysfunction due to, at least partially, persistent tachycardia leading to cellular and extracellular perturbations. Cardiomyopathy may take years to develop, but pharmacologic management to achieve rate control and reverse remodeling, as well as cardioversion or ablative strategies to stop the tachycardia, can result in rapid recovery from symptoms and gradual improvement in left ventricular ejection fraction. However, ultrastructural changes can remain and may lead to a rapid decline in ventricular function if tachycardia recurs. Ultrastructural changes may also explain a propensity toward sudden death even if the ejection fraction normalizes. Although the etiology, pathophysiology, and late clinical manifestations of tachycardia-mediated cardiomyopathy are beginning to be understood, investigation continues, focusing on prevention, early recognition, and acute and long-term management in an attempt to lessen heart failure and prevent risk of sudden death.


Cardiomyopathy Left Ventricular Ejection Fraction Amiodarone Catheter Ablation Atrial Tachycardia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sbaity S, Nerheim P, Olshansky B: Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Cardiol Rev 2007, 247:46–49.Google Scholar
  2. 2.
    Khasnis A, Jongnarangsin K, Abela G, et al.: Tachycardiainduced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 2005, 28:710–721.CrossRefPubMedGoogle Scholar
  3. 3.
    Massoure PL, Jais P, Sacher F, et al.: Tachycardia-induced right ventricular cardiomyopathy: epicardial radiofrequency ablation of an unusual and unexpected ventricular tachycardia. J Cardiovasc Electrophysiol 2009, 20:813–817.CrossRefPubMedGoogle Scholar
  4. 4.
    Nerheim P, Birger-Botkin S, Piracha L, Olshansky B: Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247–252.CrossRefPubMedGoogle Scholar
  5. 5.
    Shinbane JS, Wood MA, Jensen DN, et al.: Tachycardiainduced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997, 29:709–715.CrossRefPubMedGoogle Scholar
  6. 6.
    Calo L, De Ruvo E, Sette A, et al.: Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown) 2007, 8:138–143.Google Scholar
  7. 7.
    Luchsinger JA, Steinberg JS: Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998, 32:205–210.CrossRefPubMedGoogle Scholar
  8. 8.
    Singh B, Kaul U, Talwar KK, et al.: Reversibility of “tachycardia induced cardiomyopathy” following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996, 19:1391–1392.CrossRefPubMedGoogle Scholar
  9. 9.
    Zupan I, Rakovec P, Budihna N, et al.: Tachycardia induced cardiomyopathy in dogs; relation between chronic supraventricular and chronic ventricular tachycardia. Int J Cardiol 1996, 56:75–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Medi C, Kalman JM, Haqqani H, et al.: Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009, 53:1791–1797.CrossRefPubMedGoogle Scholar
  11. 11.
    Moe GW, Howard RJ, Grima EA, et al.: How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? J Card Fail 1995, 1:223–228.CrossRefPubMedGoogle Scholar
  12. 12.
    Tibayan FA, Lai DT, Timek TA, et al.: Alterations in left ventricular torsion in tachycardia-induced dilated cardiomyopathy. J Thorac Cardiovasc Surg 2002, 124:43–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Noe P, Van Driel V, Wittkampf F, et al.: Rapid recovery of cardiac function after catheter ablation of persistent junctional reciprocating tachycardia in children. Pacing Clin Electrophysiol 2002, 25:191–194.CrossRefPubMedGoogle Scholar
  14. 14.
    Anselme F, Boyle N, Josephson M: Incessant fascicular tachycardia: a cause of arrhythmia induced cardiomyopathy. Pacing Clin Electrophysiol 1998, 21:760–763.CrossRefPubMedGoogle Scholar
  15. 15.
    Bogun F, Crawford T, Reich S, et al.: Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007, 4:863–867.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu XK, Gersh BJ, Cha YM: Cardiomyopathy induced by pulmonary vein tachycardia cured by catheter ablation. Nat Clin Pract Cardiovasc Med 2008, 5:406–410.CrossRefPubMedGoogle Scholar
  17. 17.
    Winum PF, Cayla G, Rubini M, et al.: A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin Electrophysiol 2009, 32:942–944.CrossRefPubMedGoogle Scholar
  18. 18.
    Kuramochi Y, Guo X, Sawyer DB, et al.: Rapid electrical stimulation induces early activation of kinase signal transduction pathways and apoptosis in adult rat ventricular myocytes. Exp Physiol 2006, 91:773–780.CrossRefPubMedGoogle Scholar
  19. 19.
    Takahashi M, Tsutsui H, Kinugawa S, et al.: Role of microtubules in the contractile dysfunction of myocytes from tachycardia-induced dilated cardiomyopathy. J Mol Cell Cardiol 1998, 30:1047–1057.CrossRefPubMedGoogle Scholar
  20. 20.
    Coker ML, Thomas CV, Clair MJ, et al.: Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998, 274:H1516–H1523.PubMedGoogle Scholar
  21. 21.
    Kajstura J, Zhang X, Liu Y, et al.: The cellular basis of pacing-induced dilated cardiomyopathy. myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995, 92:2306–2317.PubMedGoogle Scholar
  22. 22.
    Zellner JL, Spinale FG, Eble DM, et al.: Alterations in myocyte shape and basement membrane attachment with tachycardiainduced heart failure. Circ Res 1991, 69:590–600.PubMedGoogle Scholar
  23. 23.
    Spinale FG, Zellner JL, Johnson WS, et al.: Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 1996, 28:1591–1608.CrossRefPubMedGoogle Scholar
  24. 24.
    Mahmoudabady M, Mathieu M, Dewachter L, et al.: Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy. J Card Fail 2008, 14:703–709.CrossRefPubMedGoogle Scholar
  25. 25.
    Spinale FG, Hendrick DA, Crawford FA, et al.: Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990, 259:H218–H229.PubMedGoogle Scholar
  26. 26.
    Omichi C, Tanaka T, Kakizawa Y, et al.: Improvement of cardiac function and neurological remodeling in a patient with tachycardia-induced cardiomyopathy after catheter ablation. J Cardiol 2009, 54:134–138.CrossRefPubMedGoogle Scholar
  27. 27.
    Deshmukh PM, Krishnamani R, Romanyshyn M, et al.: Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 2004, 13:455–458.PubMedGoogle Scholar
  28. 28.
    Ishibashi K, Osamura T, Yamahara Y: Myocardial stunning with partial aneurysmal formation generated during the recovering process of tachycardia-induced cardiomyopathy. J Cardiol 2009, 54:121–127.CrossRefPubMedGoogle Scholar
  29. 29.
    Eronen M: Outcome of fetuses with heart disease diagnosed in utero. Arch Dis Child Fetal Neonatal Ed 1997, 77:F41–F46.CrossRefPubMedGoogle Scholar
  30. 30.
    Chiu SN, Lu CW, Chang CW, et al.: Radiofrequency catheter ablation of supraventricular tachycardia in infants and toddlers. Circ J 2009, 73:1717–1721.CrossRefPubMedGoogle Scholar
  31. 31.
    Gallagher JJ: Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol 1985, 6:1172–1173.PubMedCrossRefGoogle Scholar
  32. 32.
    Jeong YH, Choi KJ, Song JM, et al.: Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008, 31:172–178.CrossRefPubMedGoogle Scholar
  33. 33.
    Dandamudi G, Rampurwala AY, Mahenthiran J, et al.: Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm 2008, 5:1111–1114.CrossRefPubMedGoogle Scholar
  34. 34.
    Middlekauff HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991, 84:40–48.PubMedGoogle Scholar
  35. 35.
    Deedwania PC, Singh BN, Ellenbogen K, et al.: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHFSTAT Investigators. Circulation 1998, 98:2574–2579.PubMedGoogle Scholar
  36. 36.
    Farshi R, Kistner D, Sarma JS, et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999, 33:304–310.CrossRefPubMedGoogle Scholar
  37. 37.
    Olshansky B, Rosenfeld LE, Warner AL, et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208.CrossRefPubMedGoogle Scholar
  38. 38.
    Van Gelder IC, Wyse DG, Chandler ML, et al.: Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006, 8:935–942.CrossRefPubMedGoogle Scholar
  39. 39.
    Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al.: Rate Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J 2006, 152:420–426.CrossRefPubMedGoogle Scholar
  40. 40.
    Fuster V, Ryden LE, Cannom DS, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257–e354.CrossRefPubMedGoogle Scholar
  41. 41.
    Narasimhan C, Blanck Z, Akhtar M: Atrioventricular nodal modification and atrioventricular junctional ablation for control of ventricular rate in atrial fibrillation. J Cardiovasc Electrophysiol 1998, 9:S146–S150.PubMedGoogle Scholar
  42. 42.
    Yamada H, Popovic ZB, Martin DO, et al.: The effects of altering time delays of coupled pacing during acute atrial fibrillation. Heart Rhythm 2006, 3:722–727.CrossRefPubMedGoogle Scholar
  43. 43.
    Botkin SB, Dhanekula LS, Olshansky B: Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J 2003, 145:233–238.CrossRefPubMedGoogle Scholar
  44. 44.
    Gopinathannair R, Olshansky B: Ibutilide revisited: stronger and safer than ever. Europace 2009, 11:9–10.CrossRefPubMedGoogle Scholar
  45. 45.
    Roy D, Talajic M, Dorian P, et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913–920.CrossRefPubMedGoogle Scholar
  46. 46.
    Roy D, Talajic M, Nattel S, et al.: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667–2677.CrossRefPubMedGoogle Scholar
  47. 47.
    Hohnloser SH, Crijns HJ, van Eickels M, et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668–678.CrossRefPubMedGoogle Scholar
  48. 48.
    Kober L, Torp-Pedersen C, McMurray JJ, et al.: Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678–2687.CrossRefPubMedGoogle Scholar
  49. 49.
    Hsu LF, Jais P, Sanders P, et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373–2383.CrossRefPubMedGoogle Scholar
  50. 50.
    Khan MN, Jais P, Cummings J, et al.: Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008, 359:1778–1785.CrossRefPubMedGoogle Scholar
  51. 51.
    Pak PH, Nuss HB, Tunin RS, et al.: Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997, 30:576–584.CrossRefPubMedGoogle Scholar
  52. 52.
    Afonso MR, Franca HH: Sudden death and tachycardiomyopathy in a young man with incessant tachycardia. Arq Bras Cardiol 1992, 58:303–306.PubMedGoogle Scholar
  53. 53.
    Watanabe H, Okamura K, Chinushi M, et al.: Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 2008, 49:39–47.CrossRefPubMedGoogle Scholar
  54. 54.
    Fox K, Borer JS, Camm AJ, et al.: Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007, 50:823–830.CrossRefPubMedGoogle Scholar
  55. 55.
    Hsia J, Larson JC, Ockene JK, et al.: Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009, 338:b219.CrossRefPubMedGoogle Scholar
  56. 56.
    Heidland UE, Strauer BE: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001, 104:1477–1482.CrossRefPubMedGoogle Scholar
  57. 57.
    Palatini P, Julius S: Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004, 26:637–644.CrossRefPubMedGoogle Scholar
  58. 58.
    Jouven X, Empana JP, Schwartz PJ, et al.: Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005, 352:1951–1958.CrossRefPubMedGoogle Scholar
  59. 59.
    Fox K, Ford I, Steg PG, et al.: Heart rate as a prognostic risk factor in patients with coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817–821.CrossRefPubMedGoogle Scholar
  60. 60.
    Okin PM, Wachtell K, Kjeldsen SE, et al.: Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhyth Electrophysiol 2008, 1:337–343.CrossRefGoogle Scholar
  61. 61.
    Gopinathannair R, Sullivan RM, Olshansky B: Slower heart rates for healthy hearts: time to redefine tachycardia? Circ Arrhythm Electrophysiol 2008, 1:321–323.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Rakesh Gopinathannair
  • Renee M. Sullivan
  • Brian Olshansky
    • 1
    Email author
  1. 1.University of Iowa HospitalsIowa CityUSA

Personalised recommendations